JournalTOCs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Subjects -> PHARMACY AND PHARMACOLOGY (Total: 575 journals)

The end of the list has been reached or no journals were found for your choice.

Most Followed Journals

Top Publishers

Top Subjects

Similar Journals

Nature Reviews Drug Discovery
Journal Prestige (SJR): 10.106

Citation Impact (citeScore): 10
Number of Followers: 334

Full-text available via subscription

Subscription journal
ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
Published by NPG

[139 journals]

Targeting protein phosphatases in cancer immunotherapy and autoimmune
disorders
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 24 January 2023; doi:10.1038/s41573-022-00618-w
  Dysregulated protein phosphorylation is implicated in numerous human diseases, but targeting protein phosphates has traditionally proved challenging. Here, Stanford and Bottini provide an overview of protein phosphatase families, focusing on their roles in autoimmunity and tumour immunity. Emerging strategies to tackle these targets and agents in development are assessed.Nature Reviews Drug Discovery, Published online: 2023-01-24; doi:10.1038/s41573-022-00618-w2023-01-24
  DOI: 10.1038/s41573-022-00618-w
The non-small-cell lung cancer drug market
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 23 January 2023; doi:10.1038/d41573-023-00017-9
  The non-small-cell lung cancer drug marketNature Reviews Drug Discovery, Published online: 2023-01-23; doi:10.1038/d41573-023-00017-92023-01-23
  DOI: 10.1038/d41573-023-00017-9
The KRAS crowd targets its next cancer mutations
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 23 January 2023; doi:10.1038/d41573-023-00015-x
  Clinic-ready inhibitors, degraders and molecular glues are pushing cancer frontiers by targeting KRAS variants including KRAS-G12D.Nature Reviews Drug Discovery, Published online: 2023-01-23; doi:10.1038/d41573-023-00015-x2023-01-23
  DOI: 10.1038/d41573-023-00015-x
Stopping stellate cell communication reverses fibrosis
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 18 January 2023; doi:10.1038/d41573-023-00016-w
  Stopping stellate cell communication reverses fibrosisNature Reviews Drug Discovery, Published online: 2023-01-18; doi:10.1038/d41573-023-00016-w2023-01-18
  DOI: 10.1038/d41573-023-00016-w
Error-corrected next-generation sequencing to advance nonclinical
genotoxicity and carcinogenicity testing
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 16 January 2023; doi:10.1038/d41573-023-00014-y
  Error-corrected next-generation sequencing (ecNGS) is an emerging technology with the potential to revolutionize the field of genetic toxicology. Here, we present recommendations from an expert working group convened to discuss potential applications, advantages and challenges associated with implementing ecNGS in nonclinical safety studies.Nature Reviews Drug Discovery, Published online: 2023-01-16; doi:10.1038/d41573-023-00014-y2023-01-16
  DOI: 10.1038/d41573-023-00014-y
2022 FDA approval number dips: a COVID-19 hangover'
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 13 January 2023; doi:10.1038/d41573-023-00007-x
  2022 FDA approval number dips: a COVID-19 hangover?Nature Reviews Drug Discovery, Published online: 2023-01-13; doi:10.1038/d41573-023-00007-x2023-01-13
  DOI: 10.1038/d41573-023-00007-x
Gene editing addresses antithrombin deficiency
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 11 January 2023; doi:10.1038/d41573-023-00008-w
  Gene editing addresses antithrombin deficiencyNature Reviews Drug Discovery, Published online: 2023-01-11; doi:10.1038/d41573-023-00008-w2023-01-11
  DOI: 10.1038/d41573-023-00008-w
Synthetic cytokine circuit targets solid tumours
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Nature Reviews Drug Discovery, Published online: 11 January 2023; doi:10.1038/d41573-023-00010-2
  Synthetic cytokine circuit targets solid tumoursNature Reviews Drug Discovery, Published online: 2023-01-11; doi:10.1038/d41573-023-00010-22023-01-11
  DOI: 10.1038/d41573-023-00010-2